Suppr超能文献

经导管三尖瓣和肺动脉瓣修复与置换

Transcatheter Tricuspid and Pulmonary Valve Repair and Replacement.

作者信息

Faries Christopher M, Sengupta Aditya, Alexis Sophia L, Tadros Rami O, Octeau David, Barnes Hanna J, Tang Gilbert H L

机构信息

Department of Surgery, Division of Vascular Surgery, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Cardiovascular Surgery, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Surg Technol Int. 2020 May 28;36:217-223.

Abstract

Severe tricuspid regurgitation (TR) is associated with significant mortality and morbidities. Currently, surgical tricuspid repair with annuloplasty is the gold standard treatment. However, the prohibitive risks of open surgery and increasing evidence that severe TR should be intervened on early has led to an outburst in the development and evolution of transcatheter tricuspid valve interventions (TTVI). These technologies are broadly categorized into direct suture annuloplasty devices, minimally invasive annuloplasty, direct ring annuloplasty devices, coaptation-based strategies, edge-to-edge repair devices, and transcatheter valve replacement. Each has its own set of advantages and limitations and have been tried, to varying degrees of success, in a myriad of pathoanatomic scenarios. Challenges faced in TTVI device and trial designs include heterogeneous patient populations, the need for quality imaging, variations of imaging requirements and anatomic criteria by device, hard-to-define clinical endpoints, and the poor prognosis carried by significant residual TR. Similar to tricuspid valve disease, pulmonic valve (PV) disease can occur on its own or secondary to a congenital heart defect, most commonly tetralogy of Fallot. Many patients with pulmonic stenosis or insufficiency often require repeat surgical interventions for other cardiac problems, highlighting the importance of developing transcatheter approaches to reduce the number of repeat open-heart surgeries required. Transcatheter PV replacement (TPVR) is growing in use and is the procedure of choice in patients with failed bioprostheses via valve-in-valve implantation. The Melody (Medtronic Inc., Minneapolis, Minnesota) and SAPIEN XT (Edwards Lifesciences Inc., Irvine, California) devices are the currently available TPVR technologies. Current limitations here include device kinking, the risk of stent fracture, anatomic difficulties, such as asymmetric right ventricular outflow tracts leading to poor landing zones and procedural risks of coronary artery and aortic root compression.

摘要

严重三尖瓣反流(TR)与显著的死亡率和发病率相关。目前,采用瓣环成形术的外科三尖瓣修复术是金标准治疗方法。然而,开胸手术的高风险以及越来越多的证据表明严重TR应尽早干预,这导致了经导管三尖瓣介入治疗(TTVI)的快速发展和演变。这些技术大致可分为直接缝合瓣环成形术装置、微创瓣环成形术、直接环瓣环成形术装置、基于贴合的策略、边对边修复装置和经导管瓣膜置换术。每种技术都有其自身的优点和局限性,并已在各种病理解剖情况下进行了不同程度的尝试,且取得了不同程度的成功。TTVI装置和试验设计面临的挑战包括患者群体异质性、对高质量成像的需求、不同装置成像要求和解剖标准的差异、难以定义的临床终点以及严重残余TR带来的不良预后。与三尖瓣疾病类似,肺动脉瓣(PV)疾病可单独发生或继发于先天性心脏缺陷,最常见的是法洛四联症。许多肺动脉狭窄或关闭不全的患者常常因其他心脏问题需要再次进行外科手术干预,这凸显了开发经导管方法以减少所需的再次开胸手术次数的重要性。经导管肺动脉瓣置换术(TPVR)的应用正在增加,并且是生物假体失败患者通过瓣中瓣植入进行治疗的首选方法。Melody(美敦力公司,明尼阿波利斯,明尼苏达州)和SAPIEN XT(爱德华兹生命科学公司,尔湾,加利福尼亚州)装置是目前可用的TPVR技术。目前这里的局限性包括装置扭结、支架骨折风险、解剖学困难,如不对称的右心室流出道导致着陆区不佳以及冠状动脉和主动脉根部受压的手术风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验